Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design
Human metapneumovirus (hMPV), a recently identified paramyxovirus, is the causative agent of respiratory tract disease in young children. Epidemiological studies have established the presence of hMPV in retrospective as well as current clinical samples in Europe, USA, Canada, Hong Kong and Australia. The hMPV disease incidence rate varied from 7 to 12 %. This rate of disease attack places hMPV in severity between respiratory syncytial virus and human parainfluenza virus type 3, two common respiratory pathogens of young children, the elderly and immunosuppressed individuals. To evaluate the effectiveness and safety of future hMPV antiviral drugs, therapeutic and prophylactic monoclonal antibodies (mAbs), and vaccine candidates, it was necessary to identify small-animal and primate models that efficiently supported hMPV replication in the respiratory tract and produced neutralizing serum antibodies, commonly a clinical correlate of protection in humans. In this study, various rodents (mice, cotton rats, hamsters and ferrets) and two primate species, rhesus macaques and African green monkeys (AGMs), were evaluated for hMPV replication in the respiratory tract. The results showed that hamsters, ferrets and AGMs supported hMPV replication efficiently and produced high levels of hMPV-neutralizing antibody titres. Hamsters vaccinated with subgroup A hMPV were protected from challenge with subgroup A or subgroup B hMPV, which has implications for hMPV vaccine design. Although these animal models do not mimic human hMPV disease signs, they will nevertheless be invaluable for the future evaluation of hMPV antivirals, mAbs and vaccines.
BoivinG.,
AbedY.,
PelletierG.,
RuelL.,
MoisanD.,
CoteS.,
PeretT. C. T.,
ErdmanD. D.,
AndersonL. J.2002; Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 186:1330–1334[CrossRef]
BuysS. B.,
du PreezJ. H.,
ElsH. J.1989; The isolation and attenuation of a virus causing rhinotracheitis in turkeys in South Africa. Onderstepoort J Vet Res 56:87–98
FreymuthF.,
VabretA.,
LeGrandL.,
EterradossiN.,
Lafay-DelaireF.,
BrouardJ.,
GuilloisB.2003; Presence of the new human metapneumovirus in French children with bronchiolitis. Pediatr Infect Dis J 22:92–94[CrossRef]
HallerA. A.,
MillerT.,
MitikuM.,
CoelinghK.2000; Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J Virol 74:11626–11635[CrossRef]
JarttiT.,
van den HoogenB.,
GarofaloR. P.,
OsterhausA. D. M. E.,
RuuskanenO.2002; Metapneumovirus and acute wheezing in children. Lancet 360:1393–1394[CrossRef]
JinH.,
ChengX.,
ZhouH. Z.,
LiS.,
SeddiquiA.2000; Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents. J Virol 74:74–82[CrossRef]
JinH.,
ChengX.,
Traina-DorgeV. L.,
ParkH. J.,
ZhouH.,
SoikeK.,
KembleG.2003; Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 21:3647–3652[CrossRef]
KarronR. A.,
BelsheR. B.,
WrightP. F.12 other authors2003; A live human parainfluenza virus type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 22:394–405
MaggiF.,
PifferiM.,
VatteroniM.9 other authors2003; Human metapneumovirus associated with respiratory tract infections in a 3-year study of nasal swabs from infants in Italy. J Clin Microbiol 41:2987–2991[CrossRef]
NissenM. D.,
SiebertD. J.,
MackayI. M.,
SlootsT. P.,
WithersS. J.2002; Evidence of human metapneumovirus in Australian children. Med J Aust 176:188–190
PeirisJ. S. M.,
TangW. H.,
ChanK. H.,
KhongP.-L.,
GuanY.,
LauY.-L.,
ChiuS. S.2003; Children with respiratory disease associated with metapneumovirus in Hong Kong. Emerg Infect Dis 9:628–633[CrossRef]
PelletierG.,
DeryP.,
AbedY.,
BoivinG.2002; Respiratory tract reinfections by the new human metapneumovirus in an immunocompromised child. Emerg Infect Dis 8:976–978[CrossRef]
PennathurS.,
HallerA. A.,
MacPhailM.11 other authors2003; Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys. J Gen Virol 84:3253–3261[CrossRef]
PeretT. C.,
BoivinG.,
LiY.,
CouillardM.,
HumphreyC.,
OsterhausA. D.,
ErdmanD. D.,
AndersonL. J.2002; Characterization of human metapneumoviruses isolated from patients in North America. J Infect Dis 185:1660–1663[CrossRef]
SkiadopoulosM. H.,
SurmanS.,
TatemJ. M.,
PaschalisM.,
WuS. L.,
UdemS. A.,
DurbinA. P.,
CollinsP. L.,
MurphyB. R.1999; Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol 73:1374–1381
TangR. S.,
SchickliJ. H.,
MacPhailM.7 other authors2003; Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3′ proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol 77:10819–10828[CrossRef]
TaoT.,
DurbinA. P.,
WhiteheadS. S.,
DavoodiF.,
CollinsP. L.,
MurphyB. R.1998; Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin–neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. J Virol 72:2955–2961
TaoT.,
DavoodiF.,
ChoC. J.,
SkiadopoulosM. H.,
DurbinA. P.,
CollinsP. L.,
MurphyB. R.2000; A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin–neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Vaccine 18:1359–1366[CrossRef]
TengM. N.,
WhiteheadS. S.,
BerminghamA.,
St ClaireM.,
ElkinsW. R.,
MurphyB. R.,
CollinsP. L.2000; Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 74:9317–9321[CrossRef]
van den HoogenB. G.,
de JongJ. C.,
GroenJ.,
KuikenT.,
de GrootR.,
FouchierR. A. M.,
OsterhausA. D. M. E.2001; A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 7:719–724[CrossRef]
van den HoogenB. G.,
BestebroerT. M.,
OsterhausA. D. M. E.,
FouchierR. A. M.2002; Analysis of the genomic sequence of a human metapneumovirus. Virology 295:119–132[CrossRef]
van den HoogenB. G.,
van DoornumG. J. J.,
FockensJ. C.,
CornelissenJ. J.,
BeyerW. E. P.,
de GrootR.,
OsterhausA. D. M. E.,
FouchierR. A. M.2003; Prevalence and clinical symptoms of human metapneumovirus infections in hospitalized patients. J Infect Dis 188:1571–1577[CrossRef]
van den HoogenB. G.,
HerfstS.,
SprongL.,
CaneP. A.,
Forleo-NetoE.,
de SwartR. L.,
OsterhausA. D. M. E.,
FouchierR. A. M.2004; Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 10 (in press
van Wyke CoelinghK. L.,
WinterC. C.,
TierneyE. L.,
LondonW. T.,
MurphyB. R.1988; Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge. J Infect Dis 157:655–662[CrossRef]
WilliamsJ. V.,
HarrisP. A.,
TollefsonS. J.,
Hallburnt-RushL. L.,
PingsterhausJ. M.,
EdwardsK. M.,
WrightP. F.,
CroweJ. E.2004; Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 350:443–450[CrossRef]
Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design